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Background: Hepatic gluconeogenesis tightly controls blood glucose levels in healthy individuals, yet disorders of
fatty acids (FAs) oxidation are characterized by hypoglycemia. We studied the ability of free-FAs to directly inhibit
gluconeogenesis, as a novel mechanism that elucidates the hypoglycemic effect of FAs oxidation defects.
Methods: Primary rat hepatocytes were pre-treated with FAs prior to gluconeogenic stimuli with glucagon or
dexamethasone and cAMP.
Results: Pre-treatment with 1 mM FAs (mixture of 2:1 oleate:palmitate) for 1 hour prior to gluconeogenic induction,
significantly decreases the induced expression of the gluconeogenic genes phosphoenolpyruvate carboxykinase
(PEPCK) and glucose-6-phosphatase (G6pase) as well as the induced glucose production by the cells. The inhibitory
effect of FAs upon gluconeogenesis is abolished when pre-treatment is elongated to 18 hours, allowing clearance
of FAs into triglycerides by the cells. Replacement of palmitate with the non-metabolic fatty acid 2-bromopalmitate
inhibits esterification of FAs into triglycerides. Accordingly, the increased exposure to unesterified-FAs allows their
inhibitory effect to be extended even when pre-treatment is elongated to 18 hours. Similar changes were caused
by FAs to the induction of peroxisome-proliferator-activated receptor-γ coactivator 1α (PGC1α) expression,
indicating this transcriptional coactivator as the mediating link of the effect. This inhibitory effect of FAs upon
gluconeogenic induction is shown to involve reduced activation of cAMP response element-binding (CREB)
transcription factor.
Conclusions: The present results demonstrate that free-FAs directly inhibit the induced gluconeogenic response in
hepatocytes. Hence, high levels of free-FAs may attenuate hepatic gluconeogenesis, and liver glucose output.
Keywords: Hypoglycemia, Liver, β-oxidation disordersBackground
The liver is a major site of systemic metabolic regula-
tion. Pathways of synthesis and degradation of lipids and
carbohydrates are controlled by complex interactions in
the hepatocytes [1]. Induction of hepatic gluconeogen-
esis (GNG) promotes the synthesis and release of glu-
cose into the blood, in order to maintain fasting
normoglycemia among healthy individuals [2]. However,
impaired glucose homeostasis, which leads to fasting-* Correspondence: otirosh@agri.huji.ac.il
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distribution, and reproduction in any mediumrelated hypoglycemia, is a prominent pathological fea-
ture of different fatty acids (FAs) oxidation disorders [3].
The main cellular site for oxidation of FAs is the mito-
chondria [4], where they are degraded in a cyclic process
of β-oxidation into acetyl-CoA units. Disorders of mito-
chondrial FAs oxidation comprise a group of at least a
dozen inherited defects of distinct enzyme or transporter
deficiencies [5]. These diseases vary in their symptoms
and severity, yet hypoglycemia is one major clinical sign
in all FAs oxidation defects [6].
The pathogenic mechanisms leading to hypoglycemia
in FAs oxidation defects have only partially been eluci-
dated [7]. The observed disruption in carbohydrate
management may result from combined effect of twod Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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enhanced peripheral glucose uptake as an outcome of
livers’ failure to produce ketone bodies [3]. Second,
hypoglycemic response might reflect reduced GNG. In
this regard, several different factors have been sug-
gested to contribute to an insufficient hepatic glucose
production among patients. Those include lack of
acetyl-CoA which is a product of FAs oxidation and
serves as allosteric activator of pyruvate carboxylase,
high levels of non-esterified acyl-CoA esters that ham-
per activation of pyruvate carboxylase, and low levels
of ATP and reducing equivalents (NADH) necessary
for GNG [8,9].
The current study shades new light on the mechanistic
basis of limited gluconeogenic capacity among patients
with defects in FAs oxidation. It is demonstrated, for the
first time, that FAs directly attenuate the induction of
gluconeogenic programme in isolated primary hepato-
cytes and that removal of FAs restores the gluconeogenic
response. Our findings indicate that free-FAs may be
involved in inhibition of GNG induction, mediating
hypoglycemia in FAs oxidation disorders.
Results
Free-FAs treatment of primary hepatocytes
Rapid uptake of FAs by cultured primary hepatocytes is
indicated by TLC separation of cellular lipid extracts.
Eminent increase in cellular FAs amounts is noticed
after 1 hour exposure to FAs (Figure 1A). Longer expos-
ure to free-FAs allows their esterification into triglycer-
ides (TGs) by the cells, as indicated by time-dependent
cellular accumulation with TGs (Figure 1B and 1C). In-
deed, as exposure of cells to FAs is elongated beyond 1
hour, free-FAs amounts decrease back to control levels
(Figure 1A and 1C), parallel to the increase in TGs
amounts.
As seen also by FACS analysis after Nile-Red staining
(Figure 1D), TGs accumulation is not evident after ex-
posure to FAs for 1 hour. Yet, as expected, massive in-
crease in cellular TGs is noticed in cells after 18 hours
exposure to free-FAs (Figure 1D). Similar results were
observed when Nile-Red stained cells were examined
under fluorescence microscopy (Figure 1E).
Replacement of palmitate acid with the non-metabolic
FA 2-bromopalmitate (FAs-Br) markedly prevented the
TGs accumulation observed after 18 hours (Figure 1D
and 1E, right lower panel). 2-bromopalmitate is not es-
terified into neutral lipids and inhibits esterification of
endogenous FAs [10] and therefore prevents TGs syn-
thesis in the cells.
Free-FAs inhibit gluconeogenesis induction
Based on the results presented in Figure 1, the effect of
free-FAs on gluconeogenesis induction was investigatedin primary hepatocytes by pre-treatment with FAs for 1
hour, prior to gluconeogenic stimuli.
Treatment of the cells with glucagon and cAMP for
6 hours induces a 16-fold increase in phosphoenolpyr-
uvate carboxykinase (PEPCK) mRNA expression level
(Figure 2A, left). PEPCK expression level is of main
importance in gluconeogenesis regulation, and therefore
is expected to be increased by this stimulus. As seen in
Figure 2A (left), pre-treatment with FAs for 1 hour, prior
to glucagon and cAMP, significantly decreases this
PEPCK induction. However, 18 hours pre-treatment
with FAs, which enables their esterification into TGs,
has no effect on PEPCK induction by glucagon and
cAMP. Accordingly, when cells are exposed to FAs-Br,
which inhibits TGs synthesis and therefore allows more
free-FAs, PEPCK induction is inhibited, even after 18
hours of pre-treatment.
Similar effects of free-FAs on PEPCK expression levels
are seen when gluconeogenesis is induced by dexa-
methasone and cAMP (Figure 2B, left).
In addition, pre-treatment with FAs for 1 hour prior
to glucagon and cAMP abolishes the induction of
glucose-6-phosphatase (G6pase) expression in primary
hepatocytes (Figure 2A, right). Like PEPCK, G6pase par-
ticipates in gluconeogenic rate control in the liver. This
inhibitory effect is also observed when cells are pre-
treated with FAs-Br, but not with FAs, for 18 hours
before gluconeogenic induction (Figure 2A, right).
Likewise, when induced by dexamethasone and cAMP,
G6pase expression is effected by the pre-treatments in
the same manner (Figure 2B, right).
As seen in Figure 2C and D, none of the treatments
altered the expression of carnitine palmitoyltransferase 1
(CPT1), the rate-limiting enzyme in long-chain FAs
β-oxidation, and of glycerol-3-phosphate acyltransferase
(GPAT), the rate-limiting enzyme in TGs synthesis.
Since both PEPCK and G6pase are rate-limiting
enzymes in the gluconeogenic pathway, the inhibition of
their induction represent the ability of free-FAs to in-
hibit induction of GNG in hepatocytes. The inhibition of
GNG by free-FAs was observed as pre-treatment with
free-FAs for 1 hour, but not for 18 hours, significantly
inhibited glucose production by hepatocytes, when
induced by glucagon and cAMP (Figure 3A) or by dexa-
methasone and cAMP (Figure 3B).The inhibitory effect of free-FAs is mediated by
attenuated peroxisome-proliferator-activated receptor-γ
coactivator 1α (PGC1α) response
The similar effect of FAs upon PEPCK and G6pase ex-
pression imply an upstream target for the inhibitory ef-





































































































































































Figure 1 (See legend on next page.)
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http://www.lipidworld.com/content/11/1/66As shown in Figure 4, pre-treatment with free-FAs for
1 hour results in a prominent inhibition of PGC1α ex-
pression, when induced by glucagon and cAMP
(Figure 4A) or by dexamethasone and cAMP (Figure 4B).In both cases, the effect of free-FAs is diminished when
pre-treatment is elongated to 18 hours, but maintained
when 18 hours pre-treatment with FAs-Br is issued
(Figure 4A and 4B). In fact, PGC1α expression is
(See figure on previous page.)
Figure 1 Uptake of free-FAs and accumulation of TGs in FAs-treated cells. Amounts of Free-FAs (A) and TGs (B) were evaluated by thin-
layer chromatography in cellular extracts of primary hepatocytes cultured with FAs mixture (2 : 1 oleate:palmitate with 1% BSA) to final
concentration of 1 mM for the indicated times. Quantification of lipid spots was performed by scanning densitometry. The bars represent the
means ± SD of the values, relatively to the corresponding control treatment, which was normalized to 100. n = 4; Comparisons were performed
using Tukey’s honestly significant differences (HSD) test. *P< .05 vs control cells cultured without FAs; †P< .05 vs cells cultured with FAs for 1
hour; { P< .05 vs cells cultured with FAs for 3 hours. (C) A representative silica gel plate separation of cellular lipid extractions is shown, with
indication of TGs and free-FAs spots position. (D) Primary hepatocytes were cultured and treated with FAs mixture (2 : 1 oleate:palmitate with 1%
BSA) or with FAs-Br mixture (2 : 1 oleate:2-Bromopalmitate with 1% BSA) to final concentration of 1 mM FAs for the indicated times. After that,
cells were stained with Nile-Red and fluorescence was measured by FACS. *P< .05 vs control cells cultured without FAs; †P< .05 vs cells cultured
with FAs for 1 hour; } P< .05 vs cells cultured with FAs-Br for 18 hours. (E) After the indicated treatments, Nile-Red stained cultures were
examined under fluorescence microscopy (magnification × 400). Yellow fluorescence indicates intracellular accumulation of TGs.
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PEPCK and G6pase, indicating that PGC1α can mediate
the inhibitory effect of FAs.Gluconeogenic response attenuation is attributed to
decreased cAMP response element-binding (CREB)
phosphorylation
As shown by the evaluation of p-CREB/CREB protein
ratio in cellular extracts, CREB activation is induced in
response to gluconeogenic stimuli of the cells with glu-
cagon and cAMP (Figure 5A) as well as with dexametha-
sone and cAMP (Figure 5B). This increase in CREB
phosphorylation levels is abolished by pre-treatment of
the cells with FAs for 1 hour before gluconeogenic in-
duction, but not by pre-treatment with FAs for 18 hours
(Figure 5A and 5B).
Hence, inhibition of CREB activation may precede the
observed effects of free-FAs on gluconeogenic response
in primary hepatocytes.Discussion
Using an in vitro model of primary hepatocytes, this
study provided the first evidence that free-FAs can dir-
ectly attenuate the activation of gluconeogenic pathway
by decreasing CREB activation. The results demonstrate
that induction of glucose production and gluconeogenic
enzymes is strongly inhibited by free-FAs in hepatocytes,
and that the mediating link of this inhibitory effect
might be inhibition of PGC1α. The inhibitory effect of
free-FAs is observed when GNG is induced by different
stimuli in hepatocytes, and relieved when they are esteri-
fied into TGs. Due to rapid esterification of FAs by the
cells, the time window for detection of this effect is
found to be short and critical. However, the duration of
the effect of free-FAs is extended when their esterifica-
tion is prevented by using non-metabolic FAs. Together,
this implies a mechanism by which GNG is suppressed
physiologically when FAs-metabolism takes over during
long term fasting in vivo. Furthermore, exceptionally
high levels of free-FAs found in the milieu of the β-oxidation deficient liver can directly attenuate GNG and
therefore facilitate hypoglycemia among patients.
Although a role for FAs in modulation of GNG was
previously suggested, it remained controversial whether
FAs affect hepatic glucose production and how [11].
Some findings imply that free-FAs increase hepatic GNG
in both healthy and diabetic individuals [12,13], as well
as in the perfused liver [14,15], and in isolated hepato-
cytes [16,17]. Yet, the mechanism underlies this pro-
posed stimulatory effect is far from being elucidated.
Due to correlation between lipid utilization and hepatic
GNG rates [16,18], the effect was mostly attributed to
increased FAs oxidation. Other data demonstrate that
FAs activate mitochondrial transport of pyruvate inde-
pendently of their oxidation [14], thus rule out that
acetyl-CoA and NADH levels are involved. Alternatively,
FAs oxidation was suggested to directly stimulate gluco-
neogenic enzymes [19].
In contrast, an inhibitory effect of FAs on hepatic
GNG has also been demonstrated both in vitro [20] and
in vivo [21]. Another study reported stimulatory as well
as inhibitory effects of FAs on glucose production in
hepatocytes, depending upon the type of FAs and the
type of gluconeogenic precursor used [22]. Therefore,
some of the inconsistency could arise from the diversity
of FAs, different exposure times, and variety of experi-
mental models used in various studies. Another explan-
ation to some of controversy might be that FAs activate
GNG only in the fed state, but not under fasting [16] or
when GNG is induced [23], and may even attenuate
GNG during fasting [24].
Our findings, indicating an inhibitory effect of FAs on
PEPCK expression in hepatocytes, are seemingly not com-
patible with several former data. Those include studies
reporting stimulation of PEPCK expression by short-chain
FAs in hepatoma cells and in primary hepatocytes, as well
as by mid-, and long-chain FAs in primary hepatocytes
[17,25]. Stimulatory effect was also demonstrated by oleate
in FaO hepatoma cell line [26], although later experiments
have failed to reproduce this result in other hepatoma cell
lines or in primary hepatocytes (reported in [27]). Anyhow,
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Figure 2 (See legend on next page.)
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http://www.lipidworld.com/content/11/1/66performed in absence of gluconeogenic stimulus, all these
previous studies reflect the effect of FAs on basal PEPCK
expression rather than the effect under inductiveconditions which was examined in the current study. The
current data indicate that free-FAs robustly attenuate the
gluconeogenic stimuli-induced PEPCK expression in
(See figure on previous page.)
Figure 2 Effect of FAs on induction of gluconeogenic genes and expression of lipid metabolism-related genes. Primary hepatocytes were
cultured and pre-treated with FAs mixture (2 : 1 oleate:palmitate with 1% BSA) or with FAs-Br mixture (2 : 1 oleate:2-Bromopalmitate with 1%
BSA) to final concentration of 1 mM FAs for the indicated times. After pre-treatments, cells were treated with the gluconeogenic inducers
glucagon and cAMP (A and C) or dexamethasone and cAMP (B and D) for 6 hours. mRNA expression levels of phosphoenolpyruvate
carboxykinase (PEPCK), glucose-6-phosphatase (G6pase), carnitine palmitoyltransferase 1 (CPT1), and glycerol-3-phosphate acyltransferase (GPAT)
were measured by quantitative real-time RT-PCR. Data are expressed as means ± SD, presented relatively to basal expression level (of cells not
pre-treated with FAs nor treated with gluconeogenic inducers), which was normalized to 1. n = 3; Comparisons were performed using Tukey’s
honestly significant differences (HSD) test. *P< .05 vs basal expression level; †P< .05 vs respective control treatment (of cells not treated with
gluconeogenic inducers); {P< .05 vs cells pre-treated for 1 hour with FAs and then treated with gluconeogenic inducers; }P< .05 vs cells






















































Figure 3 Inhibition of induced glucose release by FAs. Primary
hepatocytes were cultured and pre-treated with FAs mixture (2 : 1 oleate:
palmitate with 1% BSA) to final concentration of 1 mM FAs for the
indicated times. After pre-treatments, cells were treated with the
gluconeogenic inducers glucagon and cAMP (A) or dexamethasone and
cAMP (B) for 6 hours. Glucose output was determined by glucose
concentration measured in medium, which initially contained
gluconeogenic precursors but no glucose. Glucose levels were normalized
per million cells and are expressed as means±SD. n=3; Comparisons
were performed using Tukey’s honestly significant differences (HSD) test.
*P< .05 vs basal output level; {P< .05 vs cells pre-treated for 1 hour with
FAs and then treated with gluconeogenic inducers.
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regulation of PEPCK [27], inhibition of gene induction is
expected to be directly reflected in reduction of enzyme
activity.
G6pase was also previously investigated by a number
of studies as an optional site for FAs involvement in
GNG regulation, yet much discrepancy exists between
different in vitro and in vivo findings of FAs effect on
G6pase expression [28]. Stimulatory effect upon G6pase
expression was reported by short-chain FAs in primary
hepatocytes and hepatoma cell cultures, and by mid-
and long-chain FAs in isolated hepatocytes [17,29].
Another study found no effect of saturated and mono-
unsaturated FAs, but a suppression effect of G6pase
expression by polyunsaturated FAs in hepatoma cells
[30]. Yet again, performed in a hormone-free environ-
ment, these studies are not representative of FAs ef-
fect when GNG is physiologically induced in vivo.
It should be noted that, as seen in Figure 2, free-FAs also
create a small, not significant, decrease in basal PEPCK
and G6pase expression (of cells not stimulated with gluco-
neogenic inducers). Still, the physiological importance of
this observation is unclear, since basal expression levels
are very low relatively to the induced expression levels. An
inhibitory effect of FAs under conditions of GNG activa-
tion is in line with findings indicating suppressive effect of
FAs on GNG in the fasting state in vivo [24].
Since FAs are metabolized by hepatocytes, their effect
could be attributed to FAs per se, as well as to various
FAs-derived metabolites, acting as a relay. Yet, the rapid
effect demonstrated, obtained after 1 hour pre-treatment
with FAs, does not support the idea of metabolite-
mediated effect. In addition, the inhibitory effect
obtained using FAs-Br, containing the nonmetabolized
FA 2-bromopalmitate, is no lesser than the inhibition
caused by metabolized FAs. 2-bromopalmitate is not a
substrate for β-oxidation or TGs synthesis, and virtually
does not incorporated into neutral lipids but rather inhi-
bits FAs metabolism [31]. This implies that the effect is
generated by FAs themselves. Nevertheless, a quick in-
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Figure 4 Inhibition of PGC1α gene upregulation by FAs. Primary hepatocytes were cultured and pre-treated with FAs mixture (2 : 1 oleate:
palmitate with 1% BSA) or with FAs-Br mixture (2 : 1 oleate:2-Bromopalmitate with 1% BSA) to final concentration of 1 mM FAs for the indicated
times. After pre-treatments, cells were treated with the gluconeogenic inducers glucagon and cAMP (A) or dexamethasone and cAMP (B) for 6
hours. mRNA expression levels of PGC1α were measured by quantitative real-time RT-PCR. Data are expressed as means ± SD, presented relatively
to basal expression level (of cells not pre-treated with FAs nor treated with gluconeogenic inducers), which was normalized to 1. n = 3;
Comparisons were performed using Tukey’s honestly significant differences (HSD) test. *P< .05 vs basal expression level; †P< .05 vs respective
control treatment (of cells not treated with gluconeogenic inducers); {P< .05 vs cells pre-treated for 1 hour with FAs and then treated with
gluconeogenic inducers; }P< .05 vs cells pre-treated for 18 hours with FAs-Br and then treated with gluconeogenic inducers.
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of main lipid metabolism-related genes CPT1 and GPAT
were not affected. These results are in agreement with
previous studies indicating that long-chain FAs have no
stimulatory effect on CPT1 gene expression in primary
hepatocytes [32] and that the response of GPAT gene ex-
pression to fasting and refeeding is regulated by insulin
[33]. They imply that the inhibitory effect of free-FAs
upon the induction of gluconeogenic genes is direct, ra-
ther than created as a secondary result to changes
induced in lipid metabolism pathways. As both PEPCK
and G6pase are rate-limiting enzymes of GNG, inhib-
ition of their induction by free-FAs resulted in elimin-
ation of the cellular gluconeogenic response, reflected by
glucose release capacity of the cells (presented in
Figure 3).
Additional factor that is found to exhibit the same
inhibitability toward free-FAs as PEPCK and G6pase
genes is PGC1α induction. PGC1α is a transcriptional
coactivator, involved in expression regulation of multipleenergy metabolism-related genes in the liver. When
induced by gluconeogenic stimuli, PGC1α activates the
entire programme of gluconeogenic genes, including
PEPCK and G6pase [34], probably by interaction with
HNF-4 and the glucocorticoid receptor [2]. Therefore,
FAs can inhibit the induction of gluconeogenic genes by
downregulating the PGC1α response.
Finally, the current findings demonstrate that the
induced phosphorylation of CREB is inhibited by free-
FAs. Activated by phosphorylation at Ser 133, CREB is a
transcription factor which binds selectively to the con-
sensus cAMP responsive element (CRE) sequence found
in target genes promoters [35,36]. p-CREB induces
PGC1 gene trough CRE element found in −130 position
to transcription starting point [37]. Moreover, CRE ele-
ments are found in both PEPCK [38] and G6pase [39,40]
genes and were shown to mediate the cAMP responsive-
ness of these promoters. Therefore, the decreased CREB
activation can inhibit induction of gluconeogenic genes









































































































Figure 5 Inhibition of CREB activation by FAs. Primary
hepatocytes were cultured and pre-treated with FAs mixture (2 : 1
oleate:palmitate with 1% BSA) to final concentration of 1 mM FAs for
the indicated times. After pre-treatments, cells were treated with the
gluconeogenic inducers glucagon and cAMP (A) or dexamethasone
and cAMP (B) for 6 hours. CREB phosphorylation levels were measured
by western-blot analysis. Quantification of bands was performed by
scanning densitometry. The bars represent the means± SD of the
values, relatively to the basal expression level (of cells not pre-treated
with FAs nor treated with gluconeogenic inducers) average value,
which was normalized to 100. n = 3; Comparisons were performed
using Tukey’s honestly significant differences (HSD) test. Representative
bands are shown above bar graphs. *P< .05 vs basal expression level;
{P< .05 vs cells pre-treated for 1 hour with FAs and then treated with
gluconeogenic inducers.
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gested to mediate effects of FAs on genes expression
[41], while modification of transcription factors phos-
phorylation to alternate transactivation capacity is one
proposed mechanism [42]. Interestingly, FAs were
shown to stimulate basal GNG by PGC-1α and CREB in
isolated hepatocytes [17], supporting the involvement of
these activators in the inhibitory effect upon induced
GNG. To our knowledge, the inhibition of CREB by FAs
had not been reported hitherto.Conclusions
In summary, the presented results identify a critical role
for free-FAs as inhibitors of induced GNG, which is
mediated by influencing PGC1α and CREB-related signal-
ing. By directly attenuating gluconeogenic activation in
the β-oxidation deficient liver, high levels of free-FAs can
promote hypoglycemia. This hypothesis suggests a novel
mechanism that underlies this metabolic aberration.Methods
Animals
Rats were purchased from Harlan Laboratories and were
kept under standard conditions with 12 hours light/dark
cycles and free access to food and water. All procedures
were performed in accordance with the institutions’
guidelines of animal care.Primary hepatocytes isolation and culturing
Hepatocytes were isolated according to the method
described [43], with minor modifications. Briefly, after
anesthesia, rat livers were perfused with Hanks’ balanced
salt solution (HBSS) containing 1 mM EGTA, followed
by perfusion with 0.05% collagenase (cat.LS004177,
Worthington, Lakeswood, NJ) in HBSS in a recirculating
matter. The liver was then detached and filtered through
a 70 μm nylon mesh and cells were sedimented by cen-
trifugation. Cells were plated onto six-well plates
(700,000 cells/ml) and grown in low glucose Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% fetal calf serum, 1% L-glutamine, 100 μg/ml penicil-
lin, and 100 μg/ml streptomycin, when kept at 37°C in
humidified atmosphere (95% air and 5% CO2).Preparation of FAs
Bovine serum albumin (BSA)-complexed FAs were pre-
pared as described [44]. FAs were dissolved in ethanol at
a concentration of 100 mM. Then BSA solution (20%,
w/v) was heated to 45°C, and FAs solution was gradually
added to the BSA solution to achieve a complexed FAs
stock solution (8 mM).
Table 1 Primers used for real-time PCR
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4–6 hours after plating, culture medium was replaced
and cells were pre-treated with 1 mM FAs mixture of
BSA-complexed palmitic acid and oleic acid (1:2) for up
to 18 hours [45]. In some experiments, BSA-complexed
palmitic acid in the mixture was replaced with BSA-
complexed 2-bromopalmitate (FAs-Br treatment). Con-
trol cells were treated with appropriate vehicle solution
(composed of BSA and ethanol).
Gluconeogenic stimuli was induced by 0.1 μM gluca-
gon (cat.G2044, Sigma), or 1 μM dexamethasone (cat.
D4902, Sigma), and 1 μM Bt2cAMP (cat.D0627, Sigma)
added to the culture medium for 6 hours [34,46].
Detection of intracellular triglycerides (TGs) accumulation
Nile-Red (cat.N3010, Sigma) stock solution (1 mg/mL)
was prepared in dimethyl sulfur oxide and kept at −20°
C. Cells were washed with phosphate-buffered saline
(PBS), pH 7.4, and then incubated for 10 minutes in 37°
C with Nile-Red solution, freshly prepared in PBS at a
concentration of 1 μg/mL. Next, cells were washed again
with PBS and examined by fluorescence microscopy with
excitation at 540 nm and emission at 605 nm (Eclipse
TS100 with Epi-fluorescence Attachment; Nikon, Tokyo,
Japan) and measured by flow cytometry with excitation
at 488 nm and emission at 575 nm (FACSCalibur; Bec-
ton Dickinson, CA, USA)
Extraction of lipids from cells
Cultured cells were scraped, centrifuged, resuspended in
PBS, and sampled for determination of protein concentra-
tion by Bradford method (cat.B6916, Sigma). Cells were cen-
trifuged again, resuspended in chloroform:methanol (2:1),
and shacked gently for 30 minutes. Distilled water (20%, v/v)
was added and phases separation was accomplished by 15
minutes incubation at room temperature, followed by cen-
trifugation for 15 min at 470×g (4°C). Chloroform phase
containing lipids was collected and vacuum-dried. Pellets
were redissolved in chloroform for further analysis.
Thin-layer chromatography (TLC)
Lipid extraction samples were analyzed relative to stan-
dards on a silica gel plate (Merck, Germany), as described
[47]. The solvent system comprised petrol ether, diethyl
ether, and acetic acid in a volumetric ratio of 80 : 19 : 1.
Visualization of the compounds on the plates was per-
formed with iodine staining. Quantitative determination of
lipid spots intensity was performed by scanning
densitometry.
Total RNA isolation and quantitative real-time RT-PCR
analysis
Total RNA was isolated from the cells by using Trizol
according to the instructions of the manufacturer. cDNAwas generated by reverse transcription of 1 μg of total
RNA using High Capacity cDNA Reverse Transcription
Kit (cat.4368814, Applied Biosystems, Foster City, CA).
The expression level of mRNA was quantified with real-
time PCR by using Sybr Green qPCR mix in a 7300
Real-Time PCR System (Applied Biosystems, Foster City,
CA). The results were normalized to the Glyceraldehyde
3-phosphate dehydrogenase (GAPDH) expression (used
as endogenous control) and fold-change expression was
calculated by using Ct values in comparison with experi-
mental controls that received a value of 1. Primer
sequences used are reported in Table 1.
Glucose production assay
Culture medium was replaced with 0.4 ml of glucose pro-
duction medium consisting of glucose-free DMEM (pH
7.4), without phenol red, supplemented with 20 mM so-
dium lactate and 2 mM sodium pyruvate [34]. After 1 hour
the buffer was collected and the glucose concentration was
measured by enzymatic colorimetric glucose assay.
Western blot analysis
Cells were scraped and lysed on ice in 100 μl ice-cold RIPA
buffer [50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 4 mM
EDTA, 1% triton-X, 0.1% SDS, 1% sodium deoxycholate,
2 mM sodium orthovanadate, 5 mM NaF] with freshly
added 1 mM PMSF and protease inhibitor cocktail (cat.
P8340, Sigma). Lysates were transferred through 23 G nee-
dles, incubated on ice for 30 minutes, vigorously vortexed
and centrifuged for 15 min at 12000×g (4°C). Supernatants
were collected and used for Western blot analysis.
Determination of total protein concentrations was car-
ried out by the DC Protein Assay Reagents (cat.500-
0116, Biorad, Hercules, CA). Protein expression was
analyzed by standard Western blot techniques. In brief,
protein samples were denatured in electrophoresis buffer
Budick-Harmelin et al. Lipids in Health and Disease 2012, 11:66 Page 10 of 11
http://www.lipidworld.com/content/11/1/66(cat.S3401, Sigma), at 95°C for 5 minutes and equal
amounts of protein were subjected to sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE).
Proteins were transferred onto nitrocellulose mem-
branes, and equal loading was confirmed by ponceau red
staining. The membranes were blocked in Tris-buffered
saline with 0.1% Tween 20 (TBS-T) containing 5% non-
fat dry milk, or 5% BSA (in the case of CREB and p-
CREB, accordingly) for 1 hour at room temperature.
Immunodetection was done by using anti-CREB anti-
body (cat.9197, Cell Signaling, Danvers, MA) or anti-p-
CREB antibody (cat.9198, Cell Signaling, Danvers, MA),
diluted 1 : 1000 in TBS-T with 5% milk or 5% BSA, ac-
cordingly, at 4°C overnight. After a subsequent washing
step, peroxidase-conjugated anti-rabbit immunoglobulin
(cat.111-035-003, Jackson laboratories, West Grove, PA)
was used as a secondary antibody (diluted 1 : 3500 in
TBS-T with 2.5% milk at room temperature for 1 hour).
Visualization of immunoreactive bands was performed
by using ECL detection reagents, and the signal was
detected by short exposure to x-ray film. Bands were
quantified by scanning densitometry and expressed as
arbitrary units. Expression levels of p-CREB in each
sample were normalized to their respective CREB levels.
Statistical analysis
The results are the means ± S.D of experiments per-
formed in triplicate. Each experiment was repeated in
cells of at least two independent cell isolation proce-
dures. Analysis was performed by ANOVA using JMP
Software (SAS Institute, Cary, NC, USA). Comparisons
between groups were performed using Tukey’s honestly
significant differences (HSD) test. Differences with a
value of P< 0.05 were considered to be statistically
significant.
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